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Abstract
Background: The prevalence and burden of atherosclerotic (AS) diseases are increasing during the last twenty
years. Some studies show a close relationship between overweight and AS, but influence on AS diseases of
different weight loss methods are still studying. The purpose of the research was to study the effectiveness of a
weight loss program in AS patients in randomized controlled trial, and to develop a conception of evolution of AS.
Methods: A randomized controlled prospective clinical trial including 97 people, from them 71 patients with
various AS manifestations. Patients were divided in 2 subgroups for non-drug weight loss program, and
conventional drug therapy. The weight loss program included calorie restriction with 100–150 kcal/day, fat-free
vegetables, salt diet, and optimum physical activity. Statistical analysis was performed using SPSS for Windows
version 17.0.
Results: The weight loss subgroup lost ranging between 7-20 % from an initial weight (P = 0.016). Weight loss was
achieved due to fatty mass reduction only (P = 0.005). Hemoglobin levels (P < 0.001), bone mineral density (P < 0.001),
percentages of water (P = 0.006) and muscle masses (P = 0.0038) were increased in weight loss subgroup. Ejection
fraction (P < 0.0001), systolic output (P < 0.0001) were increased in patients with coronary artery disease. The weight
loss program led to a decrease in symptomatic drugs doses up to total abolition. A conception of AS was developed.
Conclusions: The weight loss program treated the AS diseases; improved laboratory and instrumental parameters,
decreased symptomatic drugs doses. AS development is a logical way of ontogenetic ageing of body fat.
Trial international registration: ClinicalTrials.gov NCT01700075.
Trial national registration: State registration is # 0109RK000079, code is O.0475 at the National Center for Scientific
and Technical Information of the Republic of Kazakhstan.
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Introduction
The prevalence and disease burden of Atherosclerosis
(AS) are increasing. During the last twenty years morbid-
ity and mortality form AS is globally increasing [1]. AS is
a disease affecting the blood vessels, arteries of heart,
brain and other internal organs [2]. Atherosclerotic fat,
atheroma and lipid deposits develops not only in the inner
and medial vascular layers, but also it affects the adventi-
tial layer that could be the cause of vasoconstriction wors-
ening the intravascular lumen [3].
Many "Civilization Diseases" such as metabolic syn-
drome, coronary artery disease (CAD), hypertension,
diabetes mellitus (DM), allergic diseases, non-alcoholic
fatty liver disease, psoriasis, gout, etc., have similar meta-
bolic disorders such as hyperlipidemia/dyslipidemia,
hyperglycemia, hyperinsulinemia, hypercortisolemia, hy-
peruricemia, microalbuminuria, which can be signs of
AS [4, 5]. In this case, the problem of clinical solution AS
and its clinical species are socially significant [6]. Patho-
genesis of AS is sophisticated integrative process of inter-
action of endothelial cells of arterial wall, hormonal and
metabolic abnormalities, blood components, telomere
length, etc. [7].
However, none of them has been universally recog-
nized and proved in practice up to date [8]. Last studies
show intimate relationship between obesity/overweight
and AS diseases [9]. Increased caloric intake and obesity
are recognized to shorten the lifespan [10]. Recent stud-
ies indicate that calorie restriction and intense exercise
decrease of cardiovascular disease, metabolic disease,
oxidative stress, inflammation [11, 12]. Purpose of the
research was to study the results of a weight loss pro-
gram in AS patients in randomized controlled trial. A
secondary aim of the study was to develop a conception
of evolution of AS.
Methods and participants
Study design
Open randomized controlled prospective clinical trial
with subsequent development of a conception of evolu-
tion of AS based on systematic review of scientific
databases.
Participants
We enrolled a total of 97 adult people of Asian and
European ethnicities, from them 71 were patients (34
females) with various clinical manifestation of AS aged
46.5 ± 2.3 years with body mass index (BMI) 29.7 ±
0.8 kg/m2 (patient group), and 26 healthy volunteers (12
females) aged 48.5 ± 3.7 years (healthy control group).
The patient group was divided in two subgroups. The
weight loss patient subgroup consisted from 31 patients
(16 females, aged 42–82 years, mean 47.5 ± 1.9 years,
BMI 30.1 ± 1.4 kg/m2) with various AS diseases were
randomly recruited for the weight loss program (19 Asian,
Kazakh and 12 European, Russian). The weight loss pa-
tient subgroup included next types of AS diseases: Leriche
disease (atherosclerosis of the coxofemoral artery) in 4
patients, CAD with family history more than 10 years was
present in 12 patients, CAD with postinfarction cardio-
sclerosis (PICS) in 6 patients, cerebral stroke in 7 patients,
and Alzheimer's disease in 2 patients. All the 31 patients
had hypertension, from them 19 patients had DM and the
rest 12 patients had an impaired glucose tolerance. All
enrolled AS patients had abdominal obesity and before
weight loss they took a conventional drug therapy.
The second subgroup for comparison included 40
patients with AS (18 females, aged 26–70 years, mean
45.7 ± 2.2 years, BMI 29.3 ± 1.4 kg/m2) who were receiving
a conventional drug therapy including hypoglycemic (met-
formin 500–1500 mg per day, exenatide 5–10 μg per day),
lipid lowering (atorvastatin 40 mg per day), antihyperten-
sive (lisinopril 20 mg per day, calcium channel blockers
referring to benzodiazepines 90 mg per day), anti-
inflammatory (acetylsalicylate acid up to 2 g per day and/
or thienopyridine class antiplatelet agent 75 mg per day),
and symptomatic therapy.
The study was carried out between October 2009 and
April 2012 at Scientific research institute of cardiology
and internal diseases (Almaty, the Republic of Kazakhstan)
and at Republic scientific center for emergency medicine
at National medical holding (Astana, the Republic of
Kazakhstan).
Inclusion criteria: written informed consent form for
participation in the study; dyslipidemia (blood serum
high-density lipoprotein < 1.0 mmol/l, or triglycerides ≥
1.7 mmol/l or cholesterol ≥ 5.6 mmol/l or both); body
fat% > 21; waist circumference in male > 94.0 cm or in
female > 80.0 cm; blood pressure (BP) > 140 mmHg of
systolic blood pressure (SBP) and > 95 mmHg of dia-
stolic blood pressure (DBP), or ongoing treatment with
antihypertensive drugs, fasting glucose > 6.1 mmol/l or
treatment with glucose-reducing drugs; absence of con-
traindications to weight loss; the possibility of treatment
for 6 months and dynamic observation for 1 year.
Outcome measures
The primary efficacy endpoint of the study was the
complete recovery from AS diseases. The secondary effi-
cacy endpoint of the study was data imaging methods
(doppler-ultrasound, computed tomography scans) and
measurement of clinical status presence.
Randomization
An independent statistician unconnected with clinical
practice used computer generated random numbers
(SPSS for Windows version 17.0: An IBM Company,
Armunk, NY) to prepare randomization lists. The block
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randomization was two (one on conventional drug ther-
apy, another on weight loss therapy) with stratification
by sex, age (47.5 ± 1.9 and 45.7 ± 2.2; P = 0.199) and
baseline BMI (30.1 ± 1.4 and 29.3 ± 1.4; P = 0.34).
Methods
We diagnosed CAD and PICS in patient according to
their case history and electrocardiographic changes of is-
chemia. We diagnosed hypertension by blood pressure
readings and from medical records. Abdominal obesity
was assessed waist circumference using the standards for
the Asian nationality by the International Diabetes
Federation (2005). The weight loss intervention study
period was between 2–6 months duration depending on
individual patient clinical situation, severity and stages of
disease. Physical activity was assessed as the number of
steps taken by patients, as determined by the individual
pedometer from Hoffmann-La Roche, Ltd (Basel,
Switzerland). Mental status was defined by the test of
numbers binding by Reitano [13].
We defined anthropometrical indicators including age
(years), weight (kg), BMI (kg/m2). We also evaluated
body composition parameters including as fat mass (in
% of total body weight and total kg), visceral fat rating
(units), fat free mass (kg), total body water (in % and
kg), muscle mass (in % and kg), bone mass (in % and
kg), metabolic age (years), basal metabolic rate (kcal per
day), and bioimpedance (Ohms) by using Tanita-SC330S
Body Composition Analyzer (Tanita Corp., Tokyo,
Japan). General clinical study of blood and urine chemis-
try, liver and kidneys function tests, and imaging methods
(GE Vivid 7 Ultrasound; GE Healthcare Worldwide USA,
Michigan), bone densitometry (Lunar Achilles Express
Ultrasound; GE Healthcare USA, Madison), and com-
puted tomography scans (AG Siemens Somatom Emotion
6, Germany, Muenchen) were performed.
For weight loss we used the weight loss program based
on calorie restriction, fat-free vegetables, salt diet (5–6 gr a
day), and optimum physical activity [14, 15]. The caloric
restriction included 100–150 kcal per day. There was
demanded walking with no less of 10,000 steps per day.
The exercise model is used for increase of blood circulation
and decrease of endogen metabolic intoxication. Doses of
previous symptomatic conventional drugs have been com-
petently decreased by the 2–3 day after the treatment start,
and came up to full abolition by the 7–10 day as soon as
clinical symptoms were improved. A combination of in-
person conversations and telephone calls were conducted
during the 6-month study period. Weight loss results were
assessed by BMI and the Body Composition Analyzer.
Ethics
Ethical Committee of the Scientific research institute of car-
diology and internal diseases (Phone: +7-727-2796751, +7-
727-2676851. Email: ncvb@of.kz, ncvb_cardio@of.kz) ap-
proved the study. Approval Number is in the protocol #9
from 06.02.2009. Board Affiliation: Health Ministry of the
Republic of Kazakhstan.
Statistics
The two-sample Student’s t-test and Odds ratios (ORs)
with 95 % Confidence intervals (CIs) were used. The
study data were tested on the normal distribution. The
study data are presented in Tables as Mean ± Standard
Error of the Mean (M± SE). The correlation analysis (r)
and multinomial logistic regression model ORs with CIs
were used. P-values of < 0.05 was set as significant. Statis-
tical analysis was performed using SPSS for Windows
version 17.0 (SPSS: An IBM Company, Armunk, NY) and
Microsoft Excel-2013. Databases of WEB OF SCIENCE,
SCOPUS, PUDMED, MEDSCAPE, GOOGLE SCOLAR
were used for systematic review analysis of scientific data
for working out of development conception of AS.
Results
We compared the patients and control (healthy) groups
concerning metabolic age, basal metabolic rate, anthro-
pometrical data, and body composition (Table 1).
As seen in Table 1, there were no significant differ-
ences between the patient group and the control group
regarding passport age and height. The patient group
had a significantly higher BMI for ≈ 3.5 kg/m2 compared
with the control group. Fat mass was a significantly
higher in the patient group compared with the control
group for ≈ 12.1 % or ≈ 10.0 kg. Table 1 clearly makes
the inverse relationship between Fat mass percentage
and Muscle mass percentage: the greater Fat mass per-
centage the lower Muscle mass percentage (r = − 066;
P = 0.0023).
The healthy group displayed significantly greater
percentages of Total body water +8 % (P = 0.0004),
Muscle mass +11.5 % (P < 0.0001), and bone mass +0.3 %
(P = 0.04) than the patient group. The regression linear
analysis strongly inverse correlated the relationships
between fat mass and muscle/water/bone masses in the
patient group (n = 71) (Fig. 1).
The patient group also have significantly raised visceral
fat rating (t = 3.6; P = 0.0003), metabolic age (t = 2.1;
P = 0.018), basal metabolic rate (t = 3.4; P = 0.0004), and
bioimpedance (t = 2.5; P = 0.0067) than the control group
have. Increased body fat mass is associated with accord-
ingly increased bioimpedance of the body.
As seen in Fig. 1, there are significant inverse regression
correlations between Fat mass in percent and Muscle,
Total body water, Bone masses in percent (Р < 0.0001).
This data analysis can provide evidence that Fat mass
could be the main risk factor for AS patients.
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We studied the regression correlation between the
level of obesity (fat mass in % and visceral fat level
in units) and the metabolic age in the patient group
(n = 71) (Fig. 2). As seen here, the increased parame-
ters of obesity (fat mass in %, and visceral fat level
in units) significantly correlates with the increased
metabolic age (Р < 0.0001).
We began the weight loss program in the patient
group (n = 31) who were randomly assigned into this
category. As a result of the treatment average weight lost
varied from 6 to 18 kg (or 7-20 %). No differences in
weight loss were found between patients with Asian and
European ethnicities. The weight loss led to positive
changes of the cardiovascular diseases symptoms: SBP
Table 1 Anthropometrical data, metabolic data, body composition in the comparing groups
Parameters Patient group (n = 71) Control group (n = 26) t-test P-value
M SE M SE
Passport age (years) 46.45 2.29 48.55 3.69 0.484 0.315
Weight (kg) 83.90 2.70 75.61 3.45 1.89 0.039
Height (cm) 167.93 1.12 169.27 1.99 0.587 0.279
BMI (kg/m2) 29.75 0.78 26.22 1.37 2.239 0.014
Fat mass (%) 32.40 1.28 20.27 2.67 4.097 0.00004
Fat mass (kg) 28.34 1.61 17.64 3.18 3.002 0.0017
Visceral fat rating (Unit) 10.04 0.73 6.40 0.70 3.599 0.0003
Fat free mass (kg) 54.80 1.53 58.37 2.04 1.400 0.08
Total body water (kg) 40.91 1.16 41.22 1.63 0.155 0.44
Total body water (%) 48.70 0.80 56.18 2.01 3.458 0.0004
Muscle mass (kg) 52.05 1.46 55.39 1.96 1.367 0.087
Muscle mass (%) 64.19 1.21 75.74 2.56 4.079 0.00005
Bone mass (kg) 3.16 0.07 3.01 0.10 1.229 0.111
Bone mass (%) 3.77 0.09 4.01 0.10 1.784 0.039
Metabolic age (years) 49.00 1.73 42.35 2.60 2.129 0.018
Basal metabolic rate (kcal/day) 1661.6 46.45 1419.8 52.77 3.439 0.0004
Bioimpedance (ohms) 502.10 10.30 467.42 9.11 2.522 0.0067
Abbreviations: BMI, body mass index; M, mean; SE, standard error of the mean
Fig. 1 The regression correlation between fat mass (in %) and muscle mass (in %), total body water (in %), and bone mass (in %) in the patient
group (n = 71). In a) x = fat mass (in %), y1 = muscle mass (in %), y2 = total body water (in %); in b) x = fat mass (in %), y = bone mass (in %)
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and DBP decreased in 94.4 % of patients (P < 0.001) for
more than 19 % from the initial status (Table 2).
Table 2 shows that in the conventional drug therapy
subgroup such parameters as SBP, glucose, cholesterol
and triglyceride serum levels were improved signifi-
cantly (P < 0.001). However, the conventional treat-
ment in AS patients did not lead to significant
improvement in DBP (P = 0.29), Blood hemoglobin
levels (P = 0.28), and Bone mineral density (P = 0.4).
Noteworthy, in the weight loss subgroup we observed
more significant declines in SBP, DBP, glucose, choles-
terol, and triglyceride levels (P < 0.001). There were a
significant increase in Hemoglobin levels (P < 0.001)
and Bone mineral density (P < 0.001).
The weight loss program led to weight loss ranging
between 7-20 % from an initial weight (P = 0.016).
Importantly, all of the 31 patients weight lost due to re-
duction of fat mass only (before 26.7 ± 2.9 kg, and after
15.7 ± 2.9 kg, P = 0.005; Table 3).
The data shown in the Table 3 proves that the
weight loss in AS patients was due to significant fat
loss (P = 0.005). The percentages of total body water and
muscle masses had also significant tendency to increase in
the study endpoint (P = 0.006 and = 0.0038, respectively).
Lean body mass did not significantly change with fat mass
loss (P = 0.36).
During the first 2–3 days of the treatment the most
of the patients complained of an intense feeling of
hunger, slight dizziness, weakness, lower extremity
and abdominal muscle tremor, a feeling of warm in
the umbilical and/or solar plexus area, and psycho-
genic fear due to changed eating behavior. All of
Fig. 2 Correlation between metabolic age and fat mass, and visceral fat level in the patient group (n = 71). In a) x = fat mass (in %), y = metabolic
age (years); in b) x = visceral fat level (units), y = metabolic age (years)
Table 2 Blood pressure/hemoglobin/glucose and Lipids profile, and Bone mineral density before/after treatment in the comparative
groups
Study groups SBP,
mmHg
DBP,
mmHg
Hemoglobin,
gram/L
Glucose,
mmol/L
Cholesterol,
mmol/L
Triglycerol,
gram/L
BMD,
Units
Conventional patient
subgroup, n = 40
Before treatment 149.4 ± 3.4 94.8 ± 2.2 132.1 ± 2.2 6.40 ± 0.49 5.60 ± 0.1 2.15 ± 0.05 74.0 ± 2.9
After treatment 129.6 ± 3.5 93.1 ± 2.1 134.0 ± 2.4 5.27 ± 0.37 5.24 ± 0.16 1.92 ± 0.09 73.2 ± 1.6
Weight loss patient
subgroup, n = 31
Before treatment 150.1 ± 3.9 99.3 ± 2.9 129.5 ± 2.67 6.42 ± 0.46 5.73 ± 0.13 2.31 ± 0.1 71.6 ± 2.79
After treatment 121.8 ± 2.1 81.6 ± 1.8 140.3 ± 1.6 4.37 ± 0.38 4.26 ± 0.15 1.62 ± 0.09 97.9 ± 2.8
P before and after treatment in Conventional patient
subgroup =
<0.001 0.289 0.281 0.036 0.031 0.015 0.405
P before and after treatment in Weight loss patient
subgroup =
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMD, bone mineral density
Data are presented as Means ± SE
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these uncomfortable feelings were disappearing on
subsequent days.
On the 3–5 day after start of the weight loss program
the urine of the patients was getting more turbid, muddy
and intensively colored (dark) which were not marked
before. The urine symptoms were persisted for several
days. Microscopy of the urine revealed the turbidity and
muddiness were due to the organic salts mainly, such as
oxalates, urates, phosphates, and carbonates of calcium
and magnesium. An increase in erythrocyte sedimenta-
tion rate, leukocyte count in blood samples, and body
temperature were observed between 4–10 days after
start of the weight loss program.
Regression of AS symptoms were also gradually ob-
served in the weight loss patient subgroup. The patients
noticed a physical relief, and an increase in physical and
mental workability. Doppler-ultrasound imaging data
revealed that blood flow in the lower extremities was re-
stored and the affected gastrocnemius muscle sizes were
also restored in all of the 4 patients with the Leriche dis-
ease. In CAD patients including with PICS disappeared
the angina pectoris (1.52, 95 % CI: 1.24–1.81; P = 0.034),
improved an exercise tolerance, improved objective elec-
trocardiography indicators of cardiovascular function,
increased in ejection fraction from 56.3 ± 1.1 % to 72.1 ±
1.3 % (P < 0.0001), and increased in systolic output from
65.4 ± 1.8 ml to 89.6 ± 1.7 ml (P < 0.0001). All patients
with cerebral stroke and with Alzheimer's disease no-
ticed a decrease in mental fatigue and improvement of
memory (1.47, 95 % CI: 1.18–1.77; P = 0.039).
As clinical symptoms were improved, as the doses of
previous symptomatic drugs were adequately decreased
by the 2–3 day after the treatment started. By the 7–10
day after the beginning of the treatment the drugs were
abolished. The observational period for the patients was
up to 1 year, and there was no recurrence of clinical
symptoms of the AS diseases. The weight usually was
not regained during the time period. If a person
regained overweight again, the clinical symptoms of
AS diseases have been gradually manifesting. How-
ever, these clinical symptoms were reversed if the
weight has been lost again.
Discussion
Obesity/Overweight is a global public health problem.
Overweight is widely acknowledged to be a risk factor
for a wide spectrum of cardiovascular, metabolic, neo-
plastic and musculoskeletal disorders and is estimated to
reduce life expectancy by as much as 10 years [16]. The
impact of overweight on the risk of AS diseases occur-
rence evidenced in many of the last cohort studies [17].
One of the first theories of AS development was ger-
ontological, and many researchers consider AS of vessels
as one of the determining factors of the ageing process
[10, 11]. The "oxidative stress" theory where free radicals
can affect intro intima media of arteries could become
the cause of one or other undesirable changes in the
intima [11, 18]. The inflammatory theory of AS has also
place to be that inflammatory process can be cause of
lesions of vessel intima [17, 18].
Table 3 Parameters in the weight loss patient group before and after treatment (n = 31)
Parameters Before weight loss (n = 31) After weight loss (n = 31) t-test P-value
M SE M SE
Passport age (years) 47.5 1.9 - - - -
Weight (kg) 89.56 3.59 77.91 3.39 2.359 0.016
BMI (kg/m2) 30.15 1.38 26.23 1.30 2.068 0.021
Fat mass (%) 29.87 2.01 20.23 2.55 2.969 0.0019
Fat mass (kg) 26.75 2.94 15.76 2.98 2.625 0.005
Visceral fat rating (units) 11.73 1.26 8.02 1.64 1.794 0.038
Fat free mass (kg) 62.81 2.18 60.82 2.01 0.671 0.25
Total body water (kg) 43.98 1.69 43.11 1.58 0.376 0.35
Total body water (%) 49.11 1.41 55.33 1.99 2.553 0.0061
Muscle mass (kg) 58.56 2.11 57.55 1.91 0.355 0.36
Muscle mass (%) 65.39 1.87 73.87 2.49 2.723 0.0038
Bone mass (kg) 3.26 0.12 3.05 0.10 1.344 0.091
Bone mass (%) 3.64 0.09 3.91 0.08 2.282 0.012
Metabolic age (years) 56.82 3.89 47.78 3.67 1.669 0.047
Basal metabolic rate (kcal/day) 1837.53 67.42 1495.44 64.01 3.680 0.0002
Bioimpedance (ohms) 505.00 10.22 477.54 8.95 2.021 0.023
Abbreviations: BMI, body mass index; M, mean; SE, standard error of the mean
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Hyperinsulinemia [19], dyslipidemia, insulin resistance
are the way to damage of vascular structures, endothelial
function, glucose metabolism with development of AS
processes [20, 21]. Intake of excess fats and carbohy-
drates leads to the overloading of blood transport sys-
tem. Postprandial hyperlipidemia and long-term storage
of fat leads to AS diseases [22, 23]. The hyperlipidemia
usually develops after each food intake and lasts for 6 h
or more [24, 25]. The body has a limit for storing of fat.
If the store is in “overstock” stage, then further hyperlip-
idemia leads to lipid intolerance.
Bays H. calls the unused adipose tissue as Adiposopa-
thy or "sick fat" which contributes to the emergence of
general metabolic disorders and CVD accidents [26].
Adiposopathy can be the main cause of the most cases
of adiposity-related metabolic diseases.
Due to “super-nutrient” meal regime a contemporary
human begins to accumulate more fat than he is able to
use it [27]. Permanent overnutrition changes a balance
towards lipid accumulation and deposition. The unused
lipids can transform to the body.
The more overweight the more metabolic burden for
the body’s organs and systems is [28, 29]. Overweight
causes the biological load on the body, and it requires
additional thermoregulation, synthetic, trophic, immuno-
logical, antitoxic functions, excretion of metabolic prod-
ucts from the tissue [30]. The overweight increases the
metabolic burden for the body [31, 32].
Our weight loss program is directed to metabolize
of “old lipids” [14, 15]. Weight loss led to significant
improvements of cardiovascular symptoms, objective
electrocardiography indicators, ejection fraction, sys-
tolic output, exercise tolerance and memory, decrease
in mental fatigue, etc. Our results are similar to other
studies [11, 12]. The weight loss affected fatty mass only
whereas lean mass was not significantly changed. One of
the problem during weight loss is endogen metabolic in-
toxication [33]. The exercise model was important part of
the weight loss program for cure of endogen metabolic in-
toxication. During the first few days of the weight loss
treatment patients noticed adverse effects related to the
symptoms of endogen metabolic intoxication [33]. Strat-
egies related to exercise training improvement the endo-
thelial nitric oxide and prostaglandins pathways [34].
Gender and race can influence for intention to lose
weight [35], but our study does not find any differences
in weight loss dynamic between Asian (Kazakh) and
European (Russian) ethnic groups.
In last decade the importance role of adipose tissue
in storing of organic pollutants was considered and
highlighted [36]. Adipose tissue can absorb different
persistent organic pollutants [37, 38]. Therefore, dur-
ing weight loss therapy an excretion of organic pollut-
ants from adipose tissue in blood should observe.
Consequently, we have developed a method to control
an endogen metabolic intoxication during weight loss
program.
Hypertension, hyperthermia, insulin resistance, inflam-
mation, allergy can be directed on the maintenance of
metabolic rate in the body of patients with overweight/
obesity [39, 40]. Perhaps, the process of atherosclerotic
development is a logical output of ontogenetic trans-
formation of lipids [41].
Ability to accumulate of adipose tissue is one of the
most important adaptive mechanism for survive. How-
ever, nowadays, we are eyewitnesses of another side of
the survival mechanism when obesity-related diseases
increase steadily [42]. "Since people learned to cook
food, they getting hungry twice than nature requires"
(B.Franklin, 1706–1790).
As represented in the Fig. 3 the schematic conception of
evolution of AS is related to the ontogenetic ageing of the
body fat. The main chain of the suggested conception is:
Overnutrition = >Overweight = > Limit of deposition = >
Compensatory hyperinsulinemia = > Endogen metabolic
intoxication = > Activation of protective mechanisms = >
Sealing fat and Ageing fat = > AS processes. Adipose tissue
in patients with overweight absorbs of organic metabolic
pollutants. Compensatory hyperinsulinemia leads to meta-
bolic abnormality (impaired glucose and fat tolerances,
dyslipidemia, etc.). Metabolites overload of the blood
transport system and lead to endogen metabolic intoxica-
tion. Activation of protective mechanisms (hypertension,
hyperthermia, inflammation, allergic, etc.) against of fur-
ther deposition of fat is images of chronic AS diseases.
Long term storing fat in the body leads to ageing of
the fat.
Study limitation
Published studies about possible role of overweight in
cause of AS are limited in scope and number. We ac-
knowledge that the randomized clinical trial had a small
sample size, and data of comparative or control groups
are not completely shown. The clinical results were vali-
dated by our usual scientific methods. We should per-
form the prospective randomized controlled clinical trial
with a numbers of patients for more statistical power.
Conclusions
Thus, the more fat mass is in the body the less muscle,
bone, and water masses are. Increased fat mass leads to
the increase of bioimpedance and metabolic age. We have
developed the weight loss program including a caloric re-
striction, fat-free vegetables and salt diet with optimum
physical activity is effectual treatment method of the AS
diseases. The physical activity model was important part
for cure of endogen metabolic intoxication of the weight
loss program. The program leads to positive change of
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disease symptoms, improvement in laboratory and instru-
mental parameters, and competent reduction of previous
symptomatic drugs doses up to total abolition. The main
conclusion of the study is AS development is a logical out-
put of ontogenetic ageing of body fat. The “ageing lipids”
could be used during the weight loss program. The con-
ception of evolution of AS is developed.
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